Shares of Moderna ( MRNA ), an mRNA medicines developer, sank almost 8% on Friday, pulling back from a substantial run that ...

Moderna (NASDAQ:MRNA) stock is in focus as cancer-vaccine optimism and a pending Nasdaq-100 addition anchor the mRNA developer's healthcare headlines today.

Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The ...

Today's major mRNA headline is a competitive threat to Moderna (NASDAQ:MRNA), and the stock is climbing anyway. That tension is the story on the tape, and it's worth reading as a platform bet rather ...